Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Courboulin, Audrey ^a   Tremblay, Véronique L ^a   Barrier, Marjorie ^a   Meloche, Jolyane ^a   Jacob, Maria H ^a   Chapolard, Mathilde ^a   Bisserier, Malik ^a   Paulin, Roxane ^a   Lambert, Caroline ^a   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apoptosis.; Klf5; Proliferation; Pulmonary arterial hypertension; Stat3

Indexed keywords

CYCLIN B1; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 5; PLATELET DERIVED GROWTH FACTOR; STAT3 PROTEIN; SURVIVIN; APOPTOSIS REGULATORY PROTEIN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG BIOPSY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; ADOLESCENT; ANIMAL; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADOLESCENT; ADULT; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOPHENOTYPING; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION; YOUNG ADULT;

EID: 80053351689     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-128     Document Type: Article

References (53)

1. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327(2):70-75. 10.1056/NEJM199207093270202, 1603138.
2. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 1997, 81(1):34-41.
3. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 1991, 114(6):464-469.
4. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178(1):81-88. 10.1164/rccm.200707-1037OC, 18420966.
5. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, et al. An abnormal mitochondrial-hypoxia inducible factor-1 alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006, 113(22):2630-2641. 10.1161/CIRCULATIONAHA.105.609008, 16735674.
6. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007, 104(27):11418-11423. 10.1073/pnas.0610467104, 1903339, 17596340.
7. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005, 115(6):1479-1491. 10.1172/JCI23203, 1136986, 15931388.
8. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta 2009, 403(1-2):9-16. 10.1016/j.cca.2009.01.018, 19361468.
9. Dumas de la Roque E, Savineau JP, Bonnet S. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 2010, 126(2):186-199. 10.1016/j.pharmthera.2010.02.003, 20206649.
10. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008, 31(2):407-415. 10.1183/09031936.00078207, 18238950.
11. Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg 2007, 105(4):1034-1041. table of contents, 10.1213/01.ane.0000278736.81133.26, 17898384.
12. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353(13):1412-1413. 10.1056/NEJMc051946, 16192491.
13. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000, 102(22):2781-2791.
14. Dong JT, Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 2009, 66(16):2691-2706. 10.1007/s00018-009-0045-z, 19448973.
15. Liu R, Zheng HQ, Zhou Z, Dong JT, Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem 2009, 284(25):16791-16798. 10.1074/jbc.M808919200, 2719315, 19411256.
16. Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW, et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer 2006, 118(6):1346-1355. 10.1002/ijc.21533, 16184550.
17. Sakamoto H, Sakamaki T, Kanda T, Hoshino Y, Sawada Y, Sato M, Sato H, Oyama Y, Nakano A, Takase S, et al. Smooth muscle cell outgrowth from coronary atherectomy specimens in vitro is associated with less time to restenosis and expression of a key Transcription factor KLF5/BTEB2. Cardiology 2003, 100(2):80-85. 10.1159/000073043, 14557694.
18. Nagai R, Suzuki T, Aizawa K, Shindo T, Manabe I. Significance of the transcription factor KLF5 in cardiovascular remodeling. J Thromb Haemost 2005, 3(8):1569-1576. 10.1111/j.1538-7836.2005.01366.x, 16102021.
19. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, Kawai-Kowase K, Moriyama N, Imai Y, Kawakami H, et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002, 8(8):856-863.
20. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11(1):37-51. 10.1016/j.ccr.2006.10.020, 17222789.
21. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009, 120(13):1231-1240. 10.1161/CIRCULATIONAHA.109.848911, 19752325.
22. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008, 120(2):172-185. 10.1016/j.pharmthera.2008.08.002, 18786563.
23. Grote K, Luchtefeld M, Schieffer B. JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 2005, 43(5):357-363. 10.1016/j.vph.2005.08.021, 16271517.
24. Darnell JE. STATs and gene regulation. Science 1997, 277(5332):1630-1635. 10.1126/science.277.5332.1630, 9287210.
25. Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 2007, 293(2):H1291-1299. 10.1152/ajpheart.00181.2007, 17526654.
26. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54(3):668-675. 10.1161/HYPERTENSIONAHA.109.133397, 2745434, 19597040.
27. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115(10):2811-2821. 10.1172/JCI24838, 1236676, 16200212.
28. Frasch HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999, 276(2 Pt 1):L304-310.
29. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, Hummel O, Hubner N, Savatier P. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 2009, 27(8):1760-1771. 10.1002/stem.110, 19544440.
30. Amirak E, Zakkar M, Evans PC, Kemp PR. Perfusion of veins at arterial pressure increases the expression of KLF5 and cell cycle genes in smooth muscle cells. Biochem Biophys Res Commun 2010, 391(1):818-823. 10.1016/j.bbrc.2009.11.145, 2824850, 19958749.
31. Nandan MO, Chanchevalap S, Dalton WB, Yang VW. Kruppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation. FEBS Lett 2005, 579(21):4757-4762. 10.1016/j.febslet.2005.07.053, 1626271, 16102754.
32. Yang Y, Goldstein BG, Chao HH, Katz JP. KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther 2005, 4(11):1216-1221. 10.4161/cbt.4.11.2090, 16357509.
33. He M, Han M, Zheng B, Shu YN, Wen JK. Angiotensin II stimulates KLF5 phosphorylation and its interaction with c-Jun leading to suppression of p21 expression in vascular smooth muscle cells. J Biochem 2009, 146(5):683-691. 10.1093/jb/mvp115, 19628677.
34. Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G, Shindo T, Maemura K, Kagechika H, Shudo K, et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res 2005, 97(11):1132-1141. 10.1161/01.RES.0000190613.22565.13, 16224062.
35. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005, 115(6):1479-1491. 10.1172/JCI23203, 1136986, 15931388.
36. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, Santambrogio R, Spinelli A, Coggi G, Bosari S. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 2007, 54(79):2040-2044.
37. Murakami M, Sakai H, Kodama A, Mori T, Maruo K, Yanai T, Masegi T. Expression of the anti-apoptotic factors Bcl-2 and survivin in canine vascular tumours. J Comp Pathol 2008, 139(1):1-7. 10.1016/j.jcpa.2008.02.001, 18479697.
38. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006, 17(4):597-604. 10.1093/annonc/mdj121, 16403812.
39. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. Faseb J 2005,
40. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem 2006, 281(21):14711-14718. 10.1074/jbc.M513810200, 16595680.
41. Wan H, Luo F, Wert SE, Zhang L, Xu Y, Ikegami M, Maeda Y, Bell SM, Whitsett JA. Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development 2008, 135(15):2563-2572. 10.1242/dev.021964, 18599506.
42. Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard LS, Marchesan D, Yang J, Suntharalingam J, Soon E, Exley A, et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009, 180(8):780-787. 10.1164/rccm.200810-1662OC, 2778151, 19628780.
43. Kumekawa M, Fukuda G, Shimizu S, Konno K, Odawara M. Inhibition of monocyte chemoattractant protein-1 by Kruppel-like factor 5 small interfering RNA in the tumor necrosis factor- alpha-activated human umbilical vein endothelial cells. Biol Pharm Bull 2008, 31(8):1609-1613. 10.1248/bpb.31.1609, 18670098.
44. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005, 115(9):2508-2516. 10.1172/JCI24403, 1193876, 16138193.
45. Aizawa K, Suzuki T, Kada N, Ishihara A, Kawai-Kowase K, Matsumura T, Sasaki K, Munemasa Y, Manabe I, Kurabayashi M, et al. Regulation of platelet-derived growth factor-A chain by Kruppel-like factor 5: new pathway of cooperative activation with nuclear factor-kappaB. J Biol Chem 2004, 279(1):70-76.
46. Rehman J, Archer SL. A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 2010, 661:171-185. 10.1007/978-1-60761-500-2_11, 20204730.
47. Mori A, Moser C, Lang SA, Hackl C, Gottfried E, Kreutz M, Schlitt HJ, Geissler EK, Stoeltzing O. Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1 beta signaling and hypoxia-inducible factor-1 alpha. Mol Cancer Res 2009, 7(8):1390-1398. 10.1158/1541-7786.MCR-08-0525, 19671674.
48. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009, 105(2):158-166. 10.1161/CIRCRESAHA.109.197517, 2728297, 19542014.
49. Caruso P, Maclean MR, Khanin R, McClure J, Soon E, Southwood M, McDonald RA, Greig JA, Robertson KE, Masson R, et al. Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension Due to Chronic Hypoxia and Monocrotaline. Arterioscler Thromb Vasc Biol 2010,
50. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011,
51. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Cote J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011, 123(11):1205-1215. 10.1161/CIRCULATIONAHA.110.963314, 21382889.
52. Sehgal PB, Mukhopadhyay S, Patel K, Xu F, Almodovar S, Tuder RM, Flores SC. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol 2009, 297(4):L729-737. 10.1152/ajplung.00087.2009, 2770782, 19648286.
53. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009, 104(10):1184-1191. 10.1161/CIRCRESAHA.109.197491, 19390056.